Damon Runyon’s Board of Directors

Letter from the Chairman of the Board, Mr. Alan M. Leventhal

Over its long history, the Damon Runyon Cancer Research Foundation has been a highly effective organization for two reasons:

1. the exceptional quality of the brilliant and creative early career scientists it has funded; and

2. the very generous support of people all across America who understand that we will beat cancer by investing in creative and energetic young scientists who dare to imagine, and who are hungry for new breakthroughs.

We are extremely proud of the outstanding scientists we have supported.  Their work has contributed significantly to the vast new knowledge we have about cancer and the development of innovative treatments that are bringing new hope to millions.

 

 

 

---

Our Board of Directors

CHAIRMAN
Mr. Alan M. Leventhal
Chairman and CEO
Beacon Capital Partners, LLC
Boston, Massachusetts

VICE CHAIRMAN, SCIENTIFIC PROGRAMS
David M. Livingston, MD
Deputy Director
Dana-Farber/Harvard Cancer Center
Emil Frei III Professor
Harvard Medical School
Boston, Massachusetts

VICE CHAIRMAN, FINANCE AND TREASURER
Mr. Leon G. Cooperman
Chairman and CEO
Omega Advisors, Inc.
New York, New York

VICE CHAIRMAN, AUDIT AND CORPORATE GOVERNANCE
Sanford W. Morhouse, Esq.
Of Counsel
Dewey & Leboeuf LLP
New York, New York

Mr. David M. Beirne
Partner
Benchmark Capital
Menlo Park, California

Steven J. Burakoff, MD
Director, The Tisch Cancer Institute
Mount Sinai Medical Center
New York, New York

William L. Carroll, MD
Director
NYU Cancer Institute
New York, New York

Mr. Gary E. Erlbaum
President
Greentree Properties
Ardmore, Pennsylvania

Thomas J. Fahey, Jr., MD
Senior Vice President for Clinical Program Development
Director, International Center
Memorial Sloan-Kettering Cancer Center
New York, New York

Mr. Dale F. Frey
Retired Chairman of the Board and President
General Electric Investment Corporation
Stamford, Connecticut

Mr. John A. Fry
President
Drexel University
Philadelphia, Pennsylvania

Elaine V. Fuchs, PhD
Rebecca C. Lancefield Professor
Laboratory Head
The Rockefeller University
New York, New York

Richard B. Gaynor, MD
Vice President
Cancer Research and Clinical Investigation
Eli Lilly and Company
Indianapolis, Indiana

Ms. Margaret A. Gilliam
President
Gilliam & Company
New York, New York

Todd R. Golub, MD
Director, Cancer Program
The Broad Institute of MIT and Harvard
Cambridge, Massachusetts

Mr. Michael L. Gordon
Chief Operating Officer
Angelo, Gordon & Company LP
New York, New York

Mr. Scott Greenstein
President
Entertainment and Sports
Sirius Satellite Radio
New York, New York

Mr. Jay W. Ireland
President and CEO
GE Asset Management
Stamford, Connecticut

Ronald Levy, MD
Chief, Division of Oncology
Professor of Medicine
Stanford University School of Medicine
Stanford, California

Mr. David G. Marshall
Chairman and CEO
Amerimar Realty Company
Philadelphia, Pennsylvania

Mr. John H. Myers
Senior Advisor
Angelo, Gordon & Company LP
New York, New York

Richard J. O’Reilly, MD
Chair, Department of Pediatrics
Chief, Pediatric Bone Marrow Transplant Service
Claire L. Tow Chair in Pediatric Oncology Research
Memorial Sloan-Kettering Cancer Center
New York, New York

Mrs. Katharine F. Plum
ELKABA Interiors
Hobe Sound, Florida

Mr. Andrew S. Rachleff
Partner
Benchmark Capital
Menlo Park, California

Ms. Karen D. Seitz
Managing Director
Fusion Partners
New York, New York

William R. Sellers, MD
Vice President & Global Head, Oncology
Novartis Institutes for BioMedical Research
Cambridge, Massachusetts

Samuel C. Silverstein, MD
John C. Dalton Professor
Department of Physiology and Cellular Biophysics
Columbia University
New York, New York

 

Staff of the Damon Runyon Cancer Research Foundation

Letter from the Executive Director

Dec 2009

Anyone who has ever received a cancer diagnosis knows how important it is to have an experienced and skilled physician capable of providing state-of-the-art treatment.  But we rarely pause to think about how these doctors are able to provide such care.  Every diagnostic test, every drug and every therapy regimen is a direct result of cutting-edge research by the best scientists.  In a way, the best doctors are standing on the shoulders of scientific giants.  

These scientists have brought us a long way in our ability to treat cancer.  Thanks to their work, millions are survivors.  But we all know that more progress is urgently needed.

The role of the Damon Runyon Cancer Research Foundation is to identify and support outstanding young cancer researchers who can take our ability to prevent and cure cancer to a new level.  These brilliant and fresh minds drive innovation, meeting the challenge of cancer in new ways.  Your support directly seeds this innovation.

During 2009, Damon Runyon scientists continued to make important discoveries across the full spectrum of cancer research.  Their laboratory work is accelerating our understanding of cancer every day.   Their clinical trials offer new hope to patients and families who also bravely battle this disease.

Each year, we depend on the amazing generosity of our donors to fund our young researchers.  They are today’s best young scientists and future leaders in cancer research.  With budgets still tight, your gifts will have an even greater impact.

Many thanks for your support.

Sincerely,

Lorraine W. Egan

p.s.  As always, 100% of your donation will directly support a Damon Runyon scientist.  (Our overhead is paid from Damon Runyon Broadway Tickets and our endowment.)

 

---

Staff of the Damon Runyon Cancer Research Foundation

Lorraine W. Egan
Executive Director
212.455.0541 • lorraine.egan@damonrunyon.org

AWARD PROGRAMS
Clare M. Cahill
Administrative Director
Director of Award Programs Administration
212.455.0522 • clare.cahill@damonrunyon.org

Yung S. Lie, PhD
Scientific Director
212.455.0521 • yung.lie@damonrunyon.org

Cait Ahearn
Programs Associate
212.455.0523 • cait.ahearn@damonrunyon.org

Katie Greis
Programs Assistant
212.455.0524 • katie.greis@damonrunyon.org

COMMUNICATIONS
Catherine R. Bright
Director of Communications
212.455.0506 • catherine.bright@damonrunyon.org

Todd Brogan
Communications Coordinator
212.455.0552 • todd.brogan@damonrunyon.org<

DAMON RUNYON BROADWAY TICKETS
Marialice C. Pagnotta
Director of the Damon Runyon Broadway Tickets Service
212.455.0550 • marialice.pagnotta@damonrunyon.org

DEVELOPMENT
Andrea (Andi) H. Ciminello
Director, Corporate & Foundation Relations
212.455.0504 • andrea.ciminello@damonrunyon.org

Toby Falk
Development Administrator
212.455.0502 • toby.falk@damonrunyon.org

Kristen Dempsey
Database Coordinator
212.455.0505 • kristen.dempsey@damonrunyon.org

Tegan Aherne
Development Assistant/Receptionist
212.455.0534 • tegan.aherne@damonrunyon.org

EVENTS
Kimberly Kubert
Director of Special Events
212.455.0501 • kimberly.kubert@damonrunyon.org

Liz Benham
Special Events Coordinator
212.455.0503 • liz.benham@damonrunyon.org

FINANCE
Harry Kriegel
Chief Financial Officer
212.455.0531 • harry.kriegel@damonrunyon.org

Corey Sandman
Senior Accountant / Information System Coordinator
212.455.0532 • corey.sandman@damonrunyon.org

Lillian Sun
Junior Accountant / Accounts Payable
212.455.0533 • lillian.sun@damonrunyon.org